Prosecution Insights
Last updated: April 19, 2026
Application No. 17/629,220

COMPOSITION FOR PREVENTING THE FORMATION OF SEEDS IN FRUIT

Non-Final OA §103§112
Filed
Jan 21, 2022
Examiner
AZPURU, CARLOS A
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITAT POLITÈCNICA DE VALÈNCIA
OA Round
3 (Non-Final)
84%
Grant Probability
Favorable
3-4
OA Rounds
2y 9m
To Grant
94%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
1067 granted / 1276 resolved
+23.6% vs TC avg
Moderate +10% lift
Without
With
+10.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
23 currently pending
Career history
1299
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
23.0%
-17.0% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
29.8%
-10.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1276 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114 was filed 11/03/2025. Specification The disclosure is objected to because of the following informalities: The specification is missing a Brief Description of the Drawings. Appropriate correction is required. Withdrawn Rejection The rejection of the claims under 35 USC 103 of Emmet et al in view of Cheng et al is withdrawn in view of the amendments made 11/03/2025. New Rejection(s) Based on the Amendment of 11/03/2025. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 33-40 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicant has amended the claims to read on applying the composition to the stigma rather than the flower. This is considered new matter because the original specification does not support applying to the stigma , rather than the flower. As this Examiner understands the method, an S8 sulphur compound and GA are applied in conjunction with a surfactant to the flower, which in turn promotes collapse of the stigma. The specification specifically recites applying to the blossom at page 3, lines 20-21. The method can only be carried out during the flowering stage (Page 3, line 23). Administration of the combination provokes collapse of the stigma (page 3, lines 26-27). Page 6, line 19 states that application is on the flower. At page 15, line 33 to page 16, line 1, it describes reaching the flower at the most receptive time. Treating the flower is again mentioned at page 18, line 5. Further, all the Experimental data is directed to treating the flower. Therefore applying the composition to the stigma is considered new matter. The limitation excluding grapes is also not supported by the original specification. In fact, at page 11, line 18 table grapes are specifically listed for use in this method. This is again considered new matter. Response to Amendment The affidavit under 37 CFR 1.132 filed 11/20/202 is insufficient to overcome the rejection of claims 33-38 based upon 35 USC 103 over Emmet et al in view of Cheng et al as set forth in the last Office action because: It appears to argue points already set out in the specification. The specification already teaches that gibberellic acid does not cause seedless fruit at page 16, lines 15-17. The affidavit then provides data showing that the S8 compound , when applied to the flower, produces seedless fruit. While the assertion that grapes would not produce seedless fruit , applicant is again reminded that grapes are listed for use in the instantly claimed method at page 11, line 18. The specification already teaches that the sulfur compound being applied to the flower provoked collapse of the stigma, and therefore preventing formation of seeds in the fruit at page 3, lines 28-31. Therefore the SEM and TEM photographs merely illustrate points not in dispute. The affidavit is also not commensurate in scope with the claimed method in that none of the data is directed to the use of both the S8 compound and the gibberellic acid in tandem. Further, there are no unexpected results provided by the affidavit. For these reasons, the affidavit is insufficient to overcome the rejection of the claims. Conclusion No claims are allowed. Applicant should note that once new matter is deleted from the claims, the rejection under 35 USC 103 over Emmett in view of Cheng et al will be reinstated. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to CARLOS A AZPURU whose telephone number is (571)272-0588. The examiner can normally be reached 9 am- 3 pm, 4 pm-8pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue X Liu can be reached at 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CARLOS A AZPURU/Primary Examiner, Art Unit 1617 caz
Read full office action

Prosecution Timeline

Jan 21, 2022
Application Filed
Nov 16, 2024
Non-Final Rejection — §103, §112
Feb 21, 2025
Response Filed
May 29, 2025
Final Rejection — §103, §112
Aug 29, 2025
Response after Non-Final Action
Oct 30, 2025
Applicant Interview (Telephonic)
Nov 01, 2025
Examiner Interview Summary
Nov 03, 2025
Request for Continued Examination
Nov 04, 2025
Response after Non-Final Action
Nov 20, 2025
Response after Non-Final Action
Mar 10, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589166
COMPOSITIONS AND METHODS FOR TREATING WOUNDS
2y 5m to grant Granted Mar 31, 2026
Patent 12582602
Tableted Cannabinoid Chewing Gum With Tableted Modules
2y 5m to grant Granted Mar 24, 2026
Patent 12569571
SALT RESPONSIVE NANOGELS AND NANOPARTICLES
2y 5m to grant Granted Mar 10, 2026
Patent 12569441
MICROPARTICLES AND NANOPARTICLES HAVING NEGATIVE SURFACE CHARGES
2y 5m to grant Granted Mar 10, 2026
Patent 12569457
COATED BETA HYDROXYBUTYRIC ACID CRYSTAL AND METHODS FOR PRODUCING THE SAME
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
84%
Grant Probability
94%
With Interview (+10.3%)
2y 9m
Median Time to Grant
High
PTA Risk
Based on 1276 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month